Decoy Therapeutics Inc. (DCOY) stock
DCOYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.95+0.05 (+5.37%)
Close on Nov 17, 2026Market cap $622.03KP/E –Yield –
Earnings
Decoy Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q2 FY2023
–
EPS, Q2 FY2023
-$1.43
-$0.09 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Decoy Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q2 FY2025ended Jun 30, 2025 | Jul 31, 2025after the close | – | – | – | Filing |
| Q4 FY2024ended Dec 31, 2024 | Jan 17, 2025after the close | – | – | – | Filing |
| Q2 FY2023ended Jun 30, 2023 | Aug 10, 2023after the close | – | – | -$1.43 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022before the open | – | – | -$6.41 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 15, 2022after the close | – | – | -$0.09 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 12, 2022after the close | – | – | -$0.13 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 10, 2022after the close | – | – | -$0.09 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 12, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 12, 2020before the open | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Jul 29, 2020after the close | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 14, 2020after the close | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Mar 27, 2020after the close | – | – | – | Filing |
| Q1 FY2019ended Mar 31, 2019 | May 1, 2019before the open | – | – | – | Filing |
| Q4 FY2018ended Dec 31, 2018 | Mar 6, 2019before the open | – | – | – | Filing |
| Q3 FY2018ended Sep 30, 2018 | Nov 5, 2018before the open | – | – | – | Filing |
| Q2 FY2018ended Jun 30, 2018 | Aug 1, 2018before the open | – | – | – | Filing |
| Q1 FY2018ended Mar 31, 2018 | May 2, 2018before the open | – | – | – | Filing |
| Q4 FY2017ended Dec 31, 2017 | Mar 7, 2018before the open | – | – | – | Filing |
| Q3 FY2017ended Sep 30, 2017 | Nov 6, 2017before the open | – | – | – | Filing |
| Q2 FY2017ended Jun 30, 2017 | Aug 2, 2017before the open | – | – | – | Filing |
| Q1 FY2017ended Mar 31, 2017 | May 3, 2017before the open | – | – | – | Filing |
| Q4 FY2016ended Dec 31, 2016 | Mar 8, 2017before the open | – | – | – | Filing |
| Q3 FY2016ended Sep 30, 2016 | Nov 2, 2016before the open | – | – | – | Filing |
| Q2 FY2016ended Jun 30, 2016 | Aug 3, 2016before the open | – | – | – | Filing |
| Q1 FY2016ended Mar 31, 2016 | May 4, 2016before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Decoy Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Decoy Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Decoy Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- News
- News
- News
- Update
- News
- News
- News
- News
- News
- News
- News
See a number that looks wrong?